Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 24, 2015
LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 24, 2015
LEXINGTON, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today that it has commenced an underwritten public offering of shares of its common stock. In connection...
-
Feb 3, 2015
LEXINGTON, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Jan 21, 2015Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor
LEXINGTON, Mass. and BANGALORE, India, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
-
Nov 26, 2014
LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Nov 17, 2014Trial Expected to Enroll Patients With Hormone Receptor Positive Breast Cancer and Patients With Midline Carcinoma With NUT Rearrangement
LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Nov 12, 2014
LEXINGTON, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Nov 10, 2014Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients
LEXINGTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Nov 3, 2014
LEXINGTON, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
-
Oct 28, 2014
LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Oct 2, 2014Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma
LEXINGTON, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Sep 3, 2014
LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Aug 27, 2014
LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Aug 7, 2014Management to Host Conference Call Today at 9:00 a.m. EDT
LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Jul 31, 2014
LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Jun 23, 2014Filing Triggers $3 Million Milestone Payment to Curis
LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Jun 5, 2014Expansion Phase to Include Patients With Ovarian Cancer and Certain Hematologic Malignancies
LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
-
Jun 3, 2014Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer
LEXINGTON, Mass., June 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced the...
-
May 29, 2014
LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
-
May 23, 2014
LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
May 18, 2014
LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
-
May 8, 2014Management to Host Conference Call Today at 9:00 a.m. EDT
LEXINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today...
-
May 1, 2014
LEXINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
-
Apr 30, 2014
LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
-
Apr 30, 2014Dual HDAC and PI3K Inhibitor in Ongoing Phase 1 Study in Patients With Relapsed/ Refractory Lymphoma and Multiple Myeloma
LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...